Bone metastases from prostate cancer: Assessing treatment response by using diffusion-weighted imaging and functional diffusion maps - Initial observations

Radiology

Volumn 257, Issue 2, 2010, Pages 523-531

  Reischauer, Carolin ^a   Froehlich, Johannes M ^b   Koh, Dow Mu ^c   Graf, Nicole ^d   Padevit, Christian ^b   John, Hubert ^b   Binkert, Christoph A ^b   Boesiger, Peter ^a   Gutzeit, Andreas ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DICARBOXYPROPANE 1,1 DIPHOSPHONATE TECHNETIUM TC 99M; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

AGED; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DIFFUSION; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL DIFFUSION MAP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFORMED CONSENT; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; ORCHIECTOMY; PATIENT MONITORING; PELVIC GIRDLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LINEAR MODELS; MALE; PELVIC BONES; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WHOLE BODY IMAGING;

EID: 77958595973     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10092469     Document Type: Article

References (26)

1. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88(12 Suppl):2989-2994.
2. Schellhammer PF, Sharifi R, Block NL, et al; CASODEX Combination Study Group. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: analysis of time to progression. Cancer 1996;78(10):2164-2169.
3. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419-424.
4. Wechsel HW, Gleichmann R, Blasseneck J. The behavior of prostate specific antigen (PSA) and free-PSA (f-PSA) under antihormonal therapy. Anticancer Res 2000;20(6D):4993-4994. (Pubitemid 32319067)
5. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461-3467. (Pubitemid 29517916)
6. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA metastatic androgen-independent prostate cancer. Eur Urol 2000;38(3):250-254. (Pubitemid 30665949)
7. Nakanishi K, Gutzeit A. Evaluation of malignant bone disease using DW-MRI. In: Koh DM, Thoeny HC, eds. Diffusion-weighted MR imaging. Berlin, Germany: Springer, 2010;207-226.
8. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
9. Jadvar H. Molecular imaging of prostate cancer with 18F- fluorodeoxyglucose PET. Nat Rev Urol 2009;6:317-323.
10. Huisman TA. Diffusion-weighted imaging: basic concepts and application in cerebral stroke and head trauma. Eur Radiol 2003;13(10):2283-2297.
11. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188(6):1622-1635.
12. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009;15(3):986-994.
13. Hamstra DA, Galbán CJ, Meyer CR, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008;26(20):3387-3394.
14. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008;248(3):894-900.
15. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008;111(2):213-220.
16. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A. 2005 12; 102: 5524-5529.
17. Moffat BA, Chenevert TL, Meyer CR, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8(4):259-267.
18. Lee KC, Bradley DA, Hussain M, et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007;9(12):1003-1011. (Pubitemid 350255347)
19. Nestares O, Heeger DJ. Robust multiresolution alignment of MRI brain volumes. Magn Reson Med 2000;43(5):705-715. (Pubitemid 30244270)
20. International Organization for Standardization. Accuracy (trueness and precision) of measurement methods and results: part 6-use in practice of accuracy values. Document no. 5725-6:2002-2008. Geneva, Switzerland: International Organization for Standardization, 2002;13-17.
21. Heidenreich A, Aus G, Bolla M, et al; European Association of Urology. EAU guidelines on prostate cancer [in Spanish]. Actas Urol Esp 2009;33(2):113-126.
22. Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010;39(4):333-343.
23. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22(14):2942-2953. (Pubitemid 41079914)
24. Peterson JJ. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. Semin Musculoskelet Radiol 2007;11(3):246-260.
25. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 2005;102(46):16759-16764.
26. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol 2000;10(5):415-420.